FSHD region gene 1 family member K, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG1KP profile across patient tissues and cancer cell-line models. FRG1KP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FRG1KP is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, FRG1KP RNA expression shows 11,400 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight STAD, BLCA, and ESCA as cancer lineages where FRG1KP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG1KP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG1KP survival associations across molecular data types. FRG1KP RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG1KP RNA expression–survival associations across cancer types. High FRG1KP expression shows unfavorable associations in STAD, DLBC and HNSC, but favorable associations in SKCM, BLCA and CESC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FRG1KP RNA expression.
This table summarizes FRG1KP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG1KP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG1KP shows lower tumor expression in STAD and COAD and higher tumor expression in BLCA and LUSC. The BLCA box plot shows higher FRG1KP RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p = .016).
This table shows molecular features associated with FRG1KP in patient tissues and cancer cell lines. In patient samples, FRG1KP shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
